Long-term duodenal levodopa infusion in Parkinson's disease: A 3-year motor and cognitive follow-up study

Journal of Neurology

Volumn 260, Issue 1, 2013, Pages 105-114

  Zibetti, Maurizio ^a   Merola, Aristide ^a   Ricchi, Valeria ^a   Marchisio, Alice ^a   Artusi, Carlo Alberto ^a   Rizzi, Laura ^a   Montanaro, Elisa ^a   Reggio, Dario ^b   De Angelis, Claudio ^b   Rizzone, Mario ^a   Lopiano, Leonardo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Dyskinesias; Levodopa carbidopa duodenal infusion; Motor fluctuations; Parkinson's disease

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; ENTACAPONE; HYPNOTIC AGENT; NEUROLEPTIC AGENT; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; ROPINIROLE; TOLCAPONE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COGNITION; COGNITIVE DEFECT; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; DETERIORATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INFUSION; DUODENUM PERFORATION; DYSKINESIA; EVENING DOSAGE; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFUSION PUMP; INFUSION SYSTEM; INTESTINE VOLVULUS; JEJUNOSTOMY; MALE; MEDICAL DEVICE COMPLICATION; MILD COGNITIVE IMPAIRMENT; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; OPTIMAL DRUG DOSE; PARKINSON DISEASE; PARKINSON DISEASE QUESTIONNAIRE 39; PERITONITIS; PHLEGMON; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; QUESTIONNAIRE; STOMACH TUBE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; COGNITION DISORDERS; DISABILITY EVALUATION; DRUG COMBINATIONS; DUODENUM; FEMALE; HUMANS; INFUSIONS, PARENTERAL; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; QUALITY OF LIFE; STATISTICS, NONPARAMETRIC;

EID: 84872300803     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6597-0     Document Type: Article

References (33)

1. Fernandez HH, Odin P (2011) Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr Med Res Opin 27:907-919
2. Nilsson D, Nyholm D, Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurol Scand 104:343-348
3. Kurth MC, Tetrud JW, Tanner CM et al (1993) Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 43:1698-1703
4. Nyholm D, Askmark H, Gomes-Trolin C et al (2003) Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 26:156-163
5. Nyholm D, Nilsson Remahl AI, Dizdar N et al (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216-223
6. Antonini A, Isaias IU, Canesi M et al (2007) Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 22:1145-1149
7. Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L, Pacchetti C, Zibetti M, Natuzzi F, Lopiano L, Nappi G, Pezzoli G (2008) Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 5:244-246
8. Eggert K, Schrader C, Hahn M et al (2008) Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 31:151-166
9. Puente V, De Fabregues O, Oliveras C et al (2010) Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 16:218-221
10. Santos-García D, Sanjurjo LF, Macías M, Llaneza M, Carpintero P, de la Fuente-Fernández R (2012) Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being. Acta Neurol Scand 125:187-191
11. Fasano A, Ricciardi L, Lena F, Bentivoglio AR, Modugno N (2012) Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Eur Rev Med Pharmacol Sci 16:79-89
12. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR (2009) Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468-1474
13. Devos D, French DUODOPA Study Group (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 24:993-1000
14. Nyholm D, Lewander T, Johansson A et al (2008) Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 31:63-73
15. Nyholm D, Klangemo K, Johansson A (2012) Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol. doi: 10.1111/j.1468-1331.2012.03679.x
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184
17. Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22:1689-1707
18. Nilsson D, Hansson LE, Johansson K, Nyström C, Paalzow L, Aquilonius SM (2008) Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 97:175-183
19. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25:2649-2653
20. Perozzo P, Rizzone M, Bergamasco B et al (2001) Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: comparison of pre- and postoperative neuropsychological evaluation. J Neurol Sci 192:9-15
21. Raven JC (ed) (1962) Coloured progressive matrices. Lewin, London
22. Spinnler H, Tognoni G (1987) Standardizzazione e Taratura italiana di Test Neuropsicologici. Italian J Neurol Sci 6:23-24
23. Carlesimo GA, Caltagirone C, Gainotti G, MDB Group (1996) The Mental Deterioratum Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. Eur Neurol 36:378-384
24. Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E (1996) Trail making test: normative values from 287 normal adult controls. Italian J Neurol Sci 17:305-309
25. Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB. A frontal assessment battery at bedside. Neurology 55:1621-1626
26. Freedman M, Leach L, Kaplan E, Winocur G, Shulman KJ, Delis DC (1994) Clock drawing. A neuropsichological analysis. Oxford University Press, New York
27. Zappalà G, Measso G, Cavarzean F, Grigoletto F, Lebowitz B, Pirozzolo F, Amaducci L, Massari D, Crook T (1995) Aging and memory: corrections for age, sex and education for three widely used memory tests. Italian J Neurol Sci 16:177-184
28. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH (2007) Defining mild cognitive impairment in Parkinson's disease. Mov Disord 22:1272-1277
29. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 26:353-357
30. Levy G, Schupf N, Tang MX et al (2002) Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 51:722-729
31. Foltynie T, Brayne C, Barker RA (2002) The heterogeneity of idiopathic Parkinson's disease. J Neurol 249:138-145
32. Aarsland D, Andersen K, Larsen JP et al (2006) The rate of cognitive decline in Parkinson's disease. Arch Neurol 61:1906-1911
33. Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG (2006) Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 77:585-589